Correlation between clinicopathologic factors and recurrence score according to TAILOR x risk category in patients with hormone receptor positive early-stage breast cancer

Basit Öğe Kaydı
dc.contributor.authorPilanci K.N.
dc.contributor.authorUnal C.
dc.contributor.authorOrdu C.
dc.contributor.authorGokmen E.
dc.contributor.authorOzdogan M.
dc.contributor.authorGuler N.
dc.contributor.authorUras C.
dc.date.accessioned2024-04-24T18:46:34Z
dc.date.available2024-04-24T18:46:34Z
dc.date.issued2021
dc.departmentDicle Üniversitesien_US
dc.description.abstractPurpose: Oncotype DX 21 gene recurrence score (RS) is commonly used to determine prognosis and the adjuvant therapy decision for patients with estrogen-receptor (ER)-positive, human epidermal growth factor 2(HER 2)-negative, early-stage breast cancer, especially in western countries. The use of this test is limited in Turkey due to its high cost, and the therapy decision is rather made based on clinicopathologic factors. In this study, we aimed to classify Oncotype DX RS according to the TAILOR x risk category in patients with early-stage breast cancer and to demonstrate its correlation with clinicopathologic characteristics. Methods: Oncotype DX RS was classified according to the TAILOR x risk categorization and retrospectively compared in terms of clinicopathologic characteristics in 196 patients with estrogen-receptor (ER)-positive, HER-2 negative, early-stage breast cancer. Results: Oncotype DX RS was found as ? 11 in 81.6% of the patients. Out of the patients with low recurrence scores (< 11), 75% had Luminal A and 25% had Luminal B molecular subtypes. The univariate analysis showed a significant correlation between young age (<50 years), low progesterone receptor (PR) immunoreactivity (?20%), high Ki-67 (?14) values, and high RS (?11) and the multivariate analysis found a correlation between high RS (?11), young age, and low PR immunoreactivity. There was significantly reverse correlation between age and RS. Conclusions: A significant correlation was identified between 11 and above according to the TAILOR x risk categorization and low PR immunoreactivity (?20%) and young age (<50 years) as classic clinicopathologic factors. Certain clinicopathologic parameters may not be sufficient alone to determine the treatment decision in cases where the Oncotype DX test is not accessible; however, they may have a supportive role. © 2021 Zerbinis Publications. All rights reserved.en_US
dc.identifier.endpage2273en_US
dc.identifier.issn1107-0625
dc.identifier.issue6en_US
dc.identifier.scopus2-s2.0-85123727757
dc.identifier.scopusqualityQ3
dc.identifier.startpage2266en_US
dc.identifier.urihttps://hdl.handle.net/11468/25249
dc.identifier.volume26en_US
dc.indekslendigikaynakScopus
dc.language.isoenen_US
dc.publisherZerbinis Publicationsen_US
dc.relation.ispartofJournal of B.U.ON.
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectClinicopathologic Characteristicsen_US
dc.subjectEarly-Stage Breast Canceren_US
dc.subjectOncotype Dx Recurrence Scoreen_US
dc.subjectTaılor X Risk Categorizationen_US
dc.titleCorrelation between clinicopathologic factors and recurrence score according to TAILOR x risk category in patients with hormone receptor positive early-stage breast canceren_US
dc.titleCorrelation between clinicopathologic factors and recurrence score according to TAILOR x risk category in patients with hormone receptor positive early-stage breast cancer
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu